One CRISPR infusion cut triglycerides by 63% in severe hypertriglyceridemia
Ten people living with triglyceride levels most doctors would call dangerous received a single infusion of an experimental gene-editing therapy, and a month later their triglycerides had fallen by almost two-thirds on average. The therapy, CTX310, edits a gene in the liver called ANGPTL3, and the early results were presented as a late-breaking talk at the American Heart Association's Scientific Sessions in Chicago.
The Phase 1b cohort enrolled ten adults with severe hypertriglyceridemia, a condition in which fasting triglycerides run above 500 mg/dL and can climb past 1,000. Everyone in the group started with a median level above 1,000 mg/dL. Each received one intravenous infusion, 40 mg for those under 85 kg and 50 mg for those at or above it, a flat dose designed to match the most effective dose from the earlier Phase 1a study.
By Day 30, circulating ANGPTL3 had dropped by a mean of 65% and triglycerides by 63%. Other fats moved in the same direction: non-HDL cholesterol fell 51%, apolipoprotein B 23%, and LDL cholesterol 16% from a low starting average of 60 mg/dL. Seven participants had been followed for at least 90 days, and the reductions held. Nobody in the study had an episode of acute pancreatitis, notable in a group where three in ten had suffered one before, every participant had diabetes, and two had established atherosclerotic cardiovascular disease.
The numbers come from CRISPR Therapeutics' own release of the presentation, and an independent write-up of the announcement reports the same 65% and 63% figures. No peer-reviewed paper covers this Phase 1b cohort yet; the earlier Phase 1a data, including one year of follow-up, were published in the New England Journal of Medicine after presentation at the European cardiology congress. The safety picture is likewise the company's: no serious adverse events attributed to the treatment and no meaningful rises in liver enzymes, with a single Grade 2 infusion reaction that resolved and allowed the infusion to finish.
Severe hypertriglyceridemia carries a real risk of acute pancreatitis and cardiovascular disease, and many patients stay above target on the drugs available now. The company's chief medical officer, Naimish Patel, called these the first data for CTX310 in a dedicated cohort of people with the condition, and said the team was encouraged by the scale of triglyceride lowering after a single course. The presenting cardiologist, Ashish Sarraju of Cleveland Clinic, described the results as promising and a new pathway for lipid management.
The treatment remains investigational. The US Food and Drug Administration has granted it Regenerative Medicine Advanced Therapy designations for severe hypertriglyceridemia and for elevated LDL cholesterol, and the Phase 1b trial continues at sites in the United States, the United Kingdom, Australia and New Zealand. Whether a one-time edit can keep lipids down for years, and whether that translates into fewer cases of pancreatitis and heart disease, is still to be shown.